February 7, 2012
For many months now, there has been a shortage of Doxil here in the United States. I have been too chemo-brained to fully understand it, but over the last few days, I have discovered some information that helps to make sense of the ‘Doxil Maze’. Doxil is a chemotherapy drug that has a different delivery system to the cancer cells and therefore is of great benefit to many long-term cancer patients who have become resistant to other chemotherapies. The drug works particularly well for women who have Recurrent Ovarian Cancer.
Doxil is the name for the generic drug of doxorubicin liposomal.
Ben Venue is the sole contract manufacturer of Doxil for Janssen which is a subsidiary of Johnson and Johnson. Janssen holds the patent in Doxil.
It is my understanding that there are manufacturing problems which have resulted in the nationwide Doxil shortage.